Skip to main content

Partnership with Lung Cancer Research Foundation

The EGFR Resisters has a new multi-year research partnership with the Lung Cancer Research Foundation (LCRF). LCRF is a large non-profit lung cancer advocacy organization based in New York whose mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.

For 2021, we have the opportunity to partner with LCRF to fund a new two-year $150,000 research project related to EGFR positive lung cancer. LCRF matched the money the EGFR Resisters raised dollar for dollar, so we only needed to raise $75,000 to make a difference. However, because of the enthusiastic fundraising of our members, we exceeded our goal and now have boosted our goal to $225,000. This additional amount will finance two additional research projects that we will fund through our collaboration with LCRF in 2022.

See the media release from LCRF.

Play Video

Video: Dr. Katerina Politi announces a partnership between LCRF and EGFR Resisters to fund research on EGFR-positive lung cancer. 

Partnership with LUNGevity

Christine Lovly, MD, PhD, and Helena Yu, MD, have been awarded the 2021 EGFR Resisters/LUNGevity Lung Cancer Research Award. Each award totals $200,000 for a two-year term, with funding raised by the more than 2,500 members of the EGFR Resisters, a biomarker-specific patient group that spans 75 countries.

Dr. Lovly, an associate professor of medicine and the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, won for her research, “Targeting drug tolerant states + DNA damage to block osimertinib resistance.” Dr. Yu, an assistant attending medical oncologist at Memorial Sloan Kettering Cancer Center, won for her project entitled “Molecular characterization of lineage plasticity,” which aims to identify genetic changes that contribute to histologic transformation from adenocarcinoma to small cell or squamous cell lung cancer.

“Through the funded proposals, we will investigate two major areas of unmet need in the treatment of EGFR-mutated lung cancer, and we are confident that this partnership between patients, clinical/translational researchers, and advocacy organizations will enable cutting-edge research in a collaborative, team-based manner,” Dr. Lovly said in the press release.

See the media release from LUNGevity.